drug

AVL-3288

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
DEVICE
Pre-approval / investigational in the US
Developed by University of Colorado, Denver
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
DEVICE

Indications

Trials

2
Clinical Trial of AVL-3288 in Schizophrenia Patients
NCT02978599Phase 1Completed
Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects
NCT01851603Phase 1Terminated

KOLs & investigators

2
Jeffrey A. Lieberman, MDKOL score 9
Robert Freedman, MDKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
University of Colorado, Denver
company
trial
Clinical Trial of AVL-3288 in Schizophrenia Patients
PHASE1
trial
Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects
PHASE1
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication
KOL
Jeffrey A. Lieberman, MD
KOL score 9
person
Robert Freedman, MD
KOL score 5
person